For research use only. Not for therapeutic Use.
PG-11047 (CGC-11047), a polyamine analogue, is a nonfunctional competitor of the natural polyamine spermine. PG-11047 has broad spectrum anticancer activities[1][2].
| Catalog Number | I005998 |
| CAS Number | 206991-64-2 |
| Synonyms | (Z)-N,N’-bis[3-(ethylamino)propyl]but-2-ene-1,4-diamine;tetrahydrochloride |
| Molecular Formula | C14H36Cl4N4 |
| Purity | ≥95% |
| InChI | InChI=1S/C14H32N4.4ClH/c1-3-15-11-7-13-17-9-5-6-10-18-14-8-12-16-4-2;;;;/h5-6,15-18H,3-4,7-14H2,1-2H3;4*1H/b6-5-;;;; |
| InChIKey | MNJCMBNLXQCNHO-YGGCHVFLSA-N |
| SMILES | CCNCCCNCC=CCNCCCNCC.Cl.Cl.Cl.Cl |
| Reference | [1]. Wen-Lin Kuo, et al. A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047. BMC Med. 2009 Dec 14;7:77. [2]. Murray Stewart T, et al. A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma. Cancer Chemother Pharmacol. 2021 Jan;87(1):135-144. |
